Cure8 research brief
Intestinal fibrosis and strictures remain a major cause of surgery and obstruction in Crohn’s disease, and current anti-inflammatory drugs don’t reliably prevent fibrosis. If microbial choline degradation promotes fibrosis, targeting that pathway could lead to new antifibrotic treatments for people with IBD.
Adult patients with Crohn’s disease or other IBD at risk for strictures or fibrosis; clinicians who manage IBD complications; researchers studying the microbiome or fibrosis; drug developers interested in antifibrotic strategies.
This is a funded NIH project proposing to study how gut microbial breakdown of dietary choline into trimethylamine (TMA) may drive intestinal fibrosis in IBD and whether blocking that microbial pathway can prevent or treat fibrosis.
The researchers plan three linked aims: (1) test whether TMA acting on the host receptor TAAR5 increases extracellular matrix production in intestinal fibroblasts and is altered in human IBD samples; (2) test whether selectively inhibiting microbial production of TMA reduces fibrosis in animal models; and (3) examine whether reduced epithelial choline transport (FLVCR1) predisposes to increased microbial TMA production.
The project frames microbial choline degradation as a potentially druggable target for antifibrotic therapy in IBD. This description is drawn from the NIH Reporter project abstract (project-record). It reports planned, funded research rather than completed clinical results.
This is a funded research project describing planned laboratory and preclinical work (project-record). It does not report finished clinical trials or proven therapies. Findings will need peer-reviewed publication and clinical testing before changing care.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Researchers are exploring whether gut microbes differ in patients who develop fibrous strictures — a common, surgery-prone complication of Crohn’s disease — because that could help predict risk or point to new prevention...
If correct, the paper points to a previously underappreciated immune cell (GzmK+ tissue-resident CD8+ T cells) as a potential driver of Crohn’s inflammation — which could lead to new biomarkers or therapies that work...
The study maps cell types and signals linked to submucosal scarring in Crohn's disease, a complication without drug treatments that often requires surgery. Understanding these mechanisms could point to future therapeutic...
